Form 4: Clearside Biomedical Director Thorp Clay Increases Stake with $15,000 Share Purchase

Director Thorp Clay of Clearside Biomedical, Inc. (CLSD) acquired 15,000 shares of common stock at an average price of $0.92 on February 24, 2025, increasing their total holdings.

Summary

• On February 24, 2025, Thorp Clay, a director of Clearside Biomedical, Inc. (CLSD), purchased 15,000 shares of the company's common stock.
• The shares were acquired at a weighted average price of $0.92, with individual transactions ranging from $0.90 to $0.9321.
• Following the transaction, Thorp Clay directly owns 176,141 shares of Clearside Biomedical.
• This includes 120,619 shares received as a pro rata distribution from Hatteras Venture Advisors III, LLC, Hatteras Venture Advisors IV SBIC, LLC, Hatteras Venture Advisors IV, LLC and Hatteras NC Fund, LP.
• Previously, Thorp Clay reported indirect beneficial ownership of 3,545,040 shares held by the Hatteras Entities.

Sentiment

Score: 7

Explanation: Director's purchase of shares is generally a positive sign, indicating confidence in the company. However, the size of the purchase is relatively small.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing reflects insider trading activity, which is closely monitored by investors for signals about a company's prospects. Director purchases are often viewed positively.

Stakeholder Impact

• The purchase could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Clearside Biomedical, CLSD, Thorp Clay, Director, Share Purchase, Beneficial Ownership, SEC Form 4, Hatteras Venture Advisors